These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 17716944

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. CpG-oligodeoxynucleotides enhance porcine immunity to Toxoplasma gondii.
    Kringel H, Dubey JP, Beshah E, Hecker R, Urban JF.
    Vet Parasitol; 2004 Aug 13; 123(1-2):55-66. PubMed ID: 15265571
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N, Mukherjee S, Das L, Das PK.
    Eur J Immunol; 2003 Jun 13; 33(6):1508-18. PubMed ID: 12778468
    [Abstract] [Full Text] [Related]

  • 6. Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection.
    Sánchez VR, Pitkowski MN, Fernández Cuppari AV, Rodríguez FM, Fenoy IM, Frank FM, Goldman A, Corral RS, Martin V.
    Exp Parasitol; 2011 Aug 13; 128(4):448-53. PubMed ID: 21554876
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
    Wingender G, Garbi N, Schumak B, Jüngerkes F, Endl E, von Bubnoff D, Steitz J, Striegler J, Moldenhauer G, Tüting T, Heit A, Huster KM, Takikawa O, Akira S, Busch DH, Wagner H, Hämmerling GJ, Knolle PA, Limmer A.
    Eur J Immunol; 2006 Jan 13; 36(1):12-20. PubMed ID: 16323249
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
    Jaafari MR, Badiee A, Khamesipour A, Samiei A, Soroush D, Kheiri MT, Barkhordari F, McMaster WR, Mahboudi F.
    Vaccine; 2007 Aug 10; 25(32):6107-17. PubMed ID: 17629372
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunostimulatory CpG-oligodeoxynucleotides (CpG-ODN) induce early hepatic injury, but provide a late window for protection against endotoxin-mediated liver damage.
    Slotta JE, Scheuer C, Menger MD, Vollmar B.
    J Hepatol; 2006 Mar 10; 44(3):576-85. PubMed ID: 16310279
    [Abstract] [Full Text] [Related]

  • 16. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
    Pilon-Thomas S, Li W, Briggs JJ, Djeu J, Mulé JJ, Riker AI.
    J Immunother; 2006 Mar 10; 29(4):381-7. PubMed ID: 16799333
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
    Stacey KJ, Blackwell JM.
    Infect Immun; 1999 Aug 10; 67(8):3719-26. PubMed ID: 10417129
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.